Question · Q3 2017
Keith Markey of Griffin Securities asked if the company could provide general commentary on the efficacy and safety observed in the six patients treated to date. He also inquired about potential medical conferences in the first half of 2018 where the company or its partners might present detailed findings.
Answer
CEO Paul Grint explained that due to the nature of emergency INDs, the company is dependent on the treating institutions to release data publicly first. He confirmed that the therapeutic courses have been well-tolerated but stated it was too early to comment on clinical outcomes until full data collection is complete. Regarding presentation venues, Grint noted that the patient's condition and abstract deadlines are key factors, and it's possible institutions might issue their own press releases, similar to a past case.